Neurolynx to Participate in Upcoming Investor Conferences

by Facundo Brotsky | Mar 11, 2024 | Highlight, Uncategorized

STANS, Switzerland, Feb. 25, 2024 /PRNewswire/ — Neurolynx Ltd. (Nasdaq: NLSP, NLSPW), a clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders,...

Neurolynx to Present at the LD Micro Virtual Invitational Conference on June 10, 2021

by Facundo Brotsky | Mar 11, 2024 | Left, Uncategorized

STANS, Switzerland, June 2, 2021 /PRNewswire/ — NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of...

NLS Pharmaceutics to Participate in the Canaccord Genuity 41st Annual Growth Conference

by Facundo Brotsky | Mar 11, 2024 | Left, Uncategorized

STANS, SWITZERLAND / ACCESSWIRE / August 5, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for...

Neurolynx to Present at the Access to Giving Virtual Investor Conference on July 15thNLS Satellite Symposium

by Facundo Brotsky | Mar 11, 2024 | Left, Uncategorized

STANS, SWITZERLAND / ACCESSWIRE / July 9, 2021 / Neurolynx Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) (“NRLX” or the “Company”), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients...